Ranbaxy and EPIRUS Switzerland Sign Licensing Agreement for Biosimilar Product

Ranbaxy and EPIRUS Switzerland Sign Licensing Agreement for Biosimilar Product

Gurgaon, India – Ranbaxy Laboratories Limited and EPIRUS Switzerland GmbH, a wholly-owned subsidiary of Boston-based Epirus Biopharmaceuticals, Inc., announced the signing of a licensing agreement for BOW015, a biosimilar version of Infliximab. The product will be introduced in India and other Emerging Markets. Currently, there is no biosimilar of Infliximab approved in India.

Source: Ranbaxy (link to full release)

About the author

Amitabh Arora

Amitabh Arora

Amitabh Arora has more than 18 years of experience promoting foreign direct investments (FDI), trade and economic relations between India and Switzerland, South Korea, United Kingdom and Canada. He is currently working as Director Key Accounts at the Greater Geneva Berne area (GGBa), the economic development agency of western Switzerland. GGBa offers a comprehensive range of services at no charge to foreign companies seeking to establish a presence in Switzerland. He is also the founder of FDITracker.com, tracking FDI developments worldwide. Amitabh has a Masters in International Business from the Indian Institute of Foreign Trade (IIFT) and a Bachelor of Business Studies (BBS) from College of Business Studies, India.

    Leave a Reply